Combining ulixertinib (ERK1/2 Inhibitor) with EGFR and BRAF inhibition yields significant efficacy in preclinical BRAFV600E mutant colorectal cancer models

被引：1
|
作者：
Knoerzer, Deborah
Reddy, Anupama
Box, Jessica A.
Groover, Anna
Kreider, Brent
Teresk, Martin
Emery, Caroline M.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2693
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2693
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
    Germann, Ursula A.
    Furey, Brinley F.
    Markland, William
    Hoover, Russell R.
    Aronov, Alex M.
    Roix, Jeffrey J.
    Hale, Michael
    Boucher, Diane M.
    Sorrell, David A.
    Martinez-Botella, Gabriel
    Fitzgibbon, Matthew
    Shapiro, Paul
    Wick, Michael J.
    Samadani, Ramin
    Meshaw, Kathryn
    Groover, Anna
    DeCrescenzo, Gary
    Namchuk, Mark
    Emery, Caroline M.
    Saha, Saurabh
    Welsch, Dean J.
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (11) : 2351 - 2363
  • [42] MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer
    Morimoto, Yoshihiro
    Yamashita, Nami
    Hirose, Haruka
    Fushimi, Atsushi
    Haratake, Naoki
    Daimon, Tatsuaki
    Bhattacharya, Atrayee
    Ahmad, Rehan
    Suzuki, Yozo
    Takahashi, Hidekazu
    Kufe, Donald W.
    CANCER LETTERS, 2023, 559
  • [43] Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model (vol 3, 14, 2017)
    Kirouac, Daniel C.
    Schaefer, Gabriele
    Chan, Jocelyn
    Merchant, Mark
    Orr, Christine
    Huang, Shih-Min A.
    Moffat, John
    Liu, Lichuan
    Gadkar, Kapil
    Ramanujan, Saroja
    NPJ SYSTEMS BIOLOGY AND APPLICATIONS, 2017, 3
  • [44] LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
    Vakana, Eliza
    Pratt, Susan
    Blosser, Wayne
    Dowless, Michele
    Simpson, Nicholas
    Yuan, Xiu-Juan
    Jaken, Susan
    Manro, Jason
    Stephens, Jennifer
    Zhang, Youyan
    Huber, Lysiane
    Peng, Sheng-Bin
    Stancato, Louis F.
    ONCOTARGET, 2017, 8 (06) : 9251 - 9266
  • [45] KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer
    Yeh, Jen Jen
    Routh, Elizabeth D.
    Rubinas, Tara
    Peacock, Janie
    Martin, Timothy D.
    Shen, Xiang Jun
    Sandler, Robert S.
    Kim, Hong Jin
    Keku, Temitope O.
    Der, Channing J.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (04) : 834 - 843
  • [46] Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib
    Grbcic, Petra
    Cupic, Dora Fuckar
    Gamberi, Tania
    Pavelic, Sandra Kraljevic
    Sedic, Mirela
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
  • [47] Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAFV600E Mutation Who Progressed on Cetuximab and Encorafenib With or Without Binimetinib: A Case Series
    Ji, Jingran
    Wang, Chongkai
    Fakih, Marwan
    CLINICAL COLORECTAL CANCER, 2022, 21 (03) : 267 - 271
  • [48] SYNERGISTIC EFFECT OF THE COMBINATION OF ATG-017, AN ERK1/2 INHIBITOR, AND IMMUNE CHECKPOINT INHIBITOR IN PRECLINICAL CANCER MODELS
    Chen, Peng
    Liu, Yun
    Deng, Min
    Wang, Jian
    Hoenemann, Dirk
    Lynch, Kevin
    Mei, Jay
    Shan, Bo
    Hou, Bing
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A638 - A638
  • [49] GLI1 Inhibitor SRI-38832 Attenuates Chemotherapeutic Resistance by Downregulating NBS1 Transcription in BRAFV600E Colorectal Cancer
    Zhang, Ruowen
    Ma, Jinlu
    Avery, Justin T.
    Sambandam, Vijaya
    Nguyen, Theresa H.
    Xu, Bo
    Suto, Mark J.
    Boohaker, Rebecca J.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [50] PI3′-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAFV600E/PTENNull melanoma
    Deuker, Marian M.
    Marsh-Durban, Victoria
    Phillips, Wayne A.
    Silva, Jillian M.
    McMahon, Martin
    CANCER RESEARCH, 2015, 75
12345